The Utility of the CA 19-9 Test in Patients With Pancreatic Cancer

April 10, 2014
Wen Wee Ma, MBBS

Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.

Clinical Pearls

Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.

  • CA 19-9 is a cancer marker that can be measured in the blood and is elevated in 60-70% of patients with pancreatic cancer
  • High levels of CA 19-9 in a patient who does not otherwise have clinical features of pancreatic cancer is not helpful in obtaining a diagnosis
  • CA 19-9 is primarily used in monitoring treatment response

VisitPancreatic Cancer ActionorRoswell Park Cancer Institute